IL2 Imaging in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02922283

Recruitment Status : Terminated (After an interim analysis of the data, it became clear that the imaging results did not correlate to the primary outcome measures in this subset of patients.)

First Posted : October 4, 2016

Last Update Posted : March 23, 2020

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

G.A.P. Hospers, University Medical Center Groningen

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	February 14, 2020
Actual Study Completion Date :	February 14, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

van de Donk PP, Wind TT, Hooiveld-Noeken JS, van der Veen EL, Glaudemans AWJM, Diepstra A, Jalving M, de Vries EGE, de Vries EFJ, Hospers GAP. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4369-4376. doi: 10.1007/s00259-021-05407-y. Epub 2021 Jun 2.

To Top